布洛芬是臨床上最常用的非甾體類抗炎藥之一，具有抗炎、鎮(zhèn)痛等多種藥理活性。近年來，布洛芬抗腫瘤活性受到廣泛的關(guān)注。但由于布洛芬缺乏選擇性、水溶性差且結(jié)構(gòu)中具有游離的羧基會引起胃腸道的不良反應(yīng)從而限制了其在抗癌治療中的進(jìn)一步應(yīng)用，此外布洛芬抗癌的作用機(jī)制尚未完全闡明。因此，為了提高布洛芬生物利用度，改善不良反應(yīng)并尋找新靶點(diǎn)，研究人員通過各種方法設(shè)計合成新的布洛芬衍生物。對具有抗腫瘤活性的布洛芬酰胺衍生物、酯類衍生物、金屬復(fù)合物及其他衍生物的研究進(jìn)展進(jìn)行綜述，為后續(xù)布洛芬結(jié)構(gòu)修飾物作為抗腫瘤藥物的研究、開發(fā)和利用提供借鑒和參考。

Ibuprofen, one of the most commonly used nonsteroidal anti-inflammatory drugs in clinic, has anti-inflammatory, analgesic and other pharmacological activities. In recent years, its anti-tumor activity has received extensive attention. However, due to the lack of selectivity and water solubility of ibuprofen, as well as the presence of free carboxyl groups in its structure that can cause adverse reactions in the gastrointestinal tract, its further application in anti-tumor therapy is limited. In addition, the anti-tumor mechanism of ibuprofen is not completely elucidated. Therefore, in order to improve the bioavailability and adverse effects of ibuprofen and to find new targets, researchers have designed and synthesized new ibuprofen derivatives by various methods. In this paper, the research progress of ibuprofen amide derivatives, ester derivatives, metal complexes and other derivatives with antitumor activity is reviewed to provide reference for the subsequent research, development and utilization of ibuprofen structural modifiers as anti-tumor drugs.

R979.1

湖南省自然科學(xué)基金項目（2022JJ80089）;2023年度湖南省大學(xué)生創(chuàng)新創(chuàng)業(yè)訓(xùn)練計劃一般項目（湘教通〔2023〕237號-S202310541073）